Key Summary
- MHRA issued defect notification for several batches of Quadrant Pharmaceuticals Limited's vesomni due to incorrect barcode/GTIN.
- The product is not recalled as product quality has not been impacted.
- Healthcare professionals are advised not to use this batch of medicine in robotic or automated dispensing.
The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a class 4 medicines defect notification for several batches of Quadrant Pharmaceuticals Limited's vesomni due to a barcode error.
The medicine is used to treat urinary tract problems in men.
Quadrant Pharmaceuticals informed the MHRA that their parallel imported packs of vesomni 6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton.
The GTIN printed on the affected packs is the GTIN for their parallel imported solaraze 3 percent gel 2 x 25 g packs (containing diclofenac). The other product details on the carton are correct, including name and strength.
As product quality is not compromised, the affected batches are not being recalled.
Healthcare professionals are advised not to use this batch of medicine in robotic or automated dispensing or stocking systems.
